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Abstract
Background: The role of the placenta in regulating micronutrient transport in response to maternal status is poorly
understood.
Objective: We investigated the effect of prenatal nutritional supplementation on the regulation of placental iron and
zinc transport.
Methods: In a randomized trial in rural Gambia [ENID (Early Nutrition and Immune Development)], pregnant women
were allocated to 1 of 4 nutritional intervention arms: 1) iron and folic acid (FeFol) tablets (FeFol group); 2) multiple
micronutrient (MMN) tablets (MMN group); 3) protein energy (PE) as a lipid-based nutrient supplement (LNS; PE
group); and 4) PE and MMN (PE+MMN group) as LNS. All arms included iron (60 mg/d) and folic acid (400 mg/d). The
MMN and PE+MMN arms included 30 mg supplemental Zn/d. In a subgroup of ;300 mother-infant pairs, we
measured maternal iron status, mRNA levels of genes encoding for placental iron and zinc transport proteins, and cord
blood iron levels.
Results:Maternal plasma iron concentration in late pregnancy was 45% and 78% lower in the PE and PE+MMN groups
compared to the FeFol and MMN groups, respectively (P < 0.001). The mRNA levels of the placental iron uptake protein
transferrin receptor 1 were 30–49% higher in the PE and PE+MMN arms than in the FeFol arm (P < 0.031), and also higher
in the PE+MMN arm (29%; P = 0.042) than in the MMN arm. Ferritin in infant cord blood was 18–22% lower in the LNS
groups (P < 0.024). Zinc supplementation in the MMN arm was associated with higher maternal plasma zinc
concentrations (10% increase; P < 0.001) than in other intervention arms. mRNA levels for intracellular zinc-uptake
proteins, in this case zrt, irt-like protein (ZIP) 4 and ZIP8, were 96–205% lower in the PE+MMNarm than in the intervention
arms without added zinc (P < 0.025). Furthermore, mRNA expression of ZIP1 was 85% lower in the PE+MMN group than
in the PE group (P = 0.003).
Conclusion: In conditions of lowmaternal iron and in the absence of supplemental zinc, the placenta upregulates the gene
expression of iron and zinc uptake proteins, presumably in order to meet fetal demands in the face of lowmaternal supply.
The ENID trial was registered at www.controlled-trials.com as ISRCTN49285450. J Nutr 2017;147:1401–9.
Keywords: prenatal, micronutrient, placenta, transporter, mRNA, intervention, iron, zinc, lipid-based nutrient
supplement
Introduction
Adequate maternal nutrition before and during pregnancy is
important for optimal pregnancy outcomes. However, in sub-
Saharan Africa, many women of reproductive age, especially
those living in poor rural settlements, are recognized to have
low dietary intakes of essential nutrients, contributing to de-
ficiencies (1). These nutritional deficiencies are exacerbated
during pregnancy, causing risk to both the mother and her
unborn infant. Iron and zinc deficiencies are very common.
Approximately 56% of women in sub-Saharan Africa are esti-
mated to be anemic, mainly as a result of iron deficiency (2).
Although the true extent of zinc deficiency is unknown, #80% of
women might be at risk of zinc deficiency because of habitual low
dietary zinc intake (3). Maternal nutritional deficiency is associ-
ated with poor pregnancy outcomes, including low birth weight,
small for gestational age, and prematurity (4, 5).
Prevention of nutritional deficiency during pregnancy is thus
an important public health challenge in such settings. The most
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widely used strategy is the daily supplementation of iron (60 mg)
and folic acid (400 mg) (FeFol). Because many women in resource-
poor settings suffer multiple micronutrient (MMN) deficiencies,
UNICEF/WHO/United Nations University (UNU) developed an
MMN supplement for pregnant and lactating mothers (6). How-
ever, the evidence supporting the advantages of an MMN supple-
ment over FeFol remains limited (7, 8) and alternate ways to
improve the nutritional status of pregnant and lactating women
are being explored, such as with the use of supplementary lipid-
based nutrient supplements (LNSs) (9–11). LNSs are a recently
developed group of products shown to be a very effective
option for the community-based treatment of severe malnutri-
tion if a high dose is given (e.g., reference 12). They may also
provide a route for the delivery of micronutrients that may be
preferable to and more efficacious than other products (13). In trials
of nutritional supplementation, LNSs can also be designed to
include varying amounts of protein and energy (from small to large
quantities).
Despite the increasing focus on different intervention strategies
during pregnancy, the impact of maternal nutritional status on the
regulation of nutrient transport in the human placenta, and hence
on fetal supply, is largely unknown. During pregnancy a fetus is
entirely dependent on placental transport for its nutrition; nutrients
are transported via specialized nutrient transporters located on the
placental microvillous and basal membranes (14). Evidence from
animal studies indicates that, in the presence of lowmaternal dietary
supply of micronutrients, signals from the fetus can upregulate the
expression and activity of micronutrient transporters in the placenta
to try to meet its nutritional needs (15, 16). Conversely, the expres-
sion and activity of these transporters are lower in the placenta
when maternal dietary supply is adequate. Thus placental nutrient
transporter response to maternal nutritional status is key in as-
sessing fetal nutritional accretion during pregnancy.
In a marginally nourished rural population, we investigated
the effect of nutritional supplementation during pregnancy on
maternal iron and zinc status, the expression of mRNA of iron
and zinc transporter proteins in the placentas, and the impact on
fetal cord blood iron status.
Methods
Study population
This study was nested within the prenatal arm of a randomized trial
investigating the effect of prenatal and infancy nutritional supplemen-
tation on infant immune development in rural Gambia [the ENID (Early
Nutrition and Immune Development) trial; ISRCTN49285450] (17).
The ENID trial was conducted in the West Kiang region of The
Gambia, a rural subsistence community that farms primarily groundnuts
and rice. West Kiang is ;145 km (;90 miles) inland from Banjul, the
capital of The Gambia, and has a stable resident population of ;14,000
inhabitants distributed among 36 villages. The Gambia has a tropical
climate with 2 main seasons: a hot, rainy season (June to October) and a
cooler, dry season (November to May). The beginning of the dry season
is characterized by food availability, whereas the wet season is char-
acterized by food scarcity, increased energy expenditure from farming
activities, and an increased incidence of infectious diseases (18).
Prenatal intervention and assessments
The ENID trial was a randomized, partially blind trial of nutritional
supplementation in pregnant women and their infants in the West Kiang
region of the Gambia. This nested substudy focuses on only the pre-
gnancy intervention, and so we do not describe the infants intervention.
Full details of the ENID trial protocol are published elsewhere (17).
Briefly, women between 18 and 45 y of age were invited to participate
through informed consent. Each month after enrollment, participating
women were visited by a member of the study team and completed a
short questionnaire asking about the date of their last menstrual period.
Women confirmed as being <20 wk pregnant and with a singleton pre-
gnancy were randomly assigned into the trial.
Upon entering the trial, eligible pregnant women were randomly
assigned to 1 of 4 intervention arms: 1) FeFol supplementation provided
60 mg Fe/d and 400 mg folic acid/d. This arm represents the standard of
care during pregnancy, per Gambian government guidelines. 2) MMNs
were provided as a combination of 15 micronutrients specifically
formulated for use during pregnancy by UNICEF/WHO/UNU.However,
unlike the UNICEF/WHO/UNU formulation, a single MMN tablet in
the ENID trial provided twice the RDA of all nutrients except for iron
and folate, which were kept at 60 mg/d and 400 mg/d, respectively, as in
the FeFol arm. The decision to supplement at twice the RDAwas based
on evidence from West Africa suggesting that MMNs supplemented at
twice the RDA are more effective with regard to birth outcomes (19).
Both the FeFol and MMN supplements were formulated as tablets and
manufactured by Scanpharm. 3) Protein-energy (PE), an LNS, provided
the same amounts of iron and folic acid as in the FeFol arm, but with the
addition of energy, protein, and lipids. 4) PE and MMNs (PE+MMN), a
micronutrient-fortified LNS supplement providing the same amounts
of micronutrients as in the MMN arm (including FeFol), in addition
to the energy, protein, and lipid content. The 2 LNS products were
manufactured by Valid Nutrition, Nairobi, Kenya. The composition of
each of the 4 prenatal nutritional intervention arms is detailed inTable 1.
Details of the procedure randomizing and allocating women to the
intervention arms were outlined in the published trial protocol (17).
Data and blood sample collection during pregnancy
At enrollment (‘‘booking’’) and at 20 and 30 wk of gestation, women
attended the Medical Research Council (MRC) Keneba clinic for a de-
tailed antenatal assessment. A standard antenatal check, including blood
pressure measurement and hemoglobin and urine analyses, was performed
at each visit. In addition, data on maternal anthropometry, including
weight, height, waist and hip circumferences, and midupper arm circum-
ference, were collected. Gestational age was determined by ultrasound. All
measurements were made using standard, regularly validated equipment
and following the relevant standard operating procedures. At each visit,
after an overnight fast, a sample of venous blood (20 mL) was collected in
trace element–free tubes (Sarstedt AG&Co), and aliquots of plasma were
prepared and stored for subsequent analysis.
Sample collection at birth
In this community, the majority of women choose to deliver in their
homes with the support of a traditional birth attendant. Through a
network of field workers, deliveries in both homes and health centers
were attended, when possible, by a midwife or traditional birth attendant.
For home deliveries, field assistants residing in the village attended the
delivery to collect cord blood and the placenta. The sample of cord blood
(#15 mL) was collected immediately after delivery. The placenta was then
sealed in a sterile plastic bag and transported on ice, with the cord blood,
to the MRC Keneba laboratory for processing (20).
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Within 72 h of delivery, a trained midwife conducted neonatal
anthropometry, including weight, length, midupper arm circumference,
and head circumference.
Laboratory analysis
Assessment of maternal iron and zinc status during pregnancy.
Whole-blood samples collected from the women at booking and 20 and
30 wk of gestation were used to assess hemoglobin concentration
using a Medonic hematology analyzer (Clinical Diagnostic Solutions,
Inc.). Plasma samples from the same time points were later assessed for
the following panel of iron indicators: ferritin, serum soluble transferrin
receptor (sTfR), hepcidin, transferrin, unbound iron-binding capacity
(UIBC), and iron. Plasma ferritin, transferrin, iron, and UIBC were
quantified using an automated multianalyte analyzer (COBAS INTEGRA
400 plus; Roche Diagnostics). Plasma hepcidin was quantified by
competitive ELISA [Hepcidin-25 (human) ELISA kit; Bachem), accord-
ing to the manufacturers instruction. Plasma sTfR was quantified
using a Quantikine IVD ELISA kit (R&D Systems), according to the
manufacturers instructions. Cord blood samples were analyzed for
only hemoglobin, iron, and ferritin.
Only maternal blood samples collected at 30 wk of gestation were
analyzed for plasma zinc, using an inductively coupled plasma mass
spectrometer (7700 series; Agilent Technologies). Before inductively
coupled plasma mass spectrometry, the plasma samples were predigested
with nitric acid. This involved adding 40 mL ultragrade nitric acid (60%
w/w; Merck) and 10 mL hydrogen peroxide (30% w/w; Sigma-Aldrich)
to 50 mL plasma. The mixture was heated at 80C for 40 min on a hot
block, allowed to cool to room temperature, then diluted with ultrapure
water (1:20). Trace element control (trace elements serum 1; Seronorm;
Sero AS) was analyzed alongside the samples as a quality control. Five
replicatedmeasures of the samples, control, and standards were analyzed
and the mean taken as the concentration of zinc in parts per billion.
Measures in parts per billion were converted to micromoles per liter,
with the molecular weight of zinc taken as 65.38 g/mol.
Placental sample processing. Placental samples were processed
according to a standard protocol adapted from Pasupathy et al. (21).
Upon arrival at the laboratory, the placentas were weighed using a digital
scale, and the length, breadth, and thickness were measured with a
graduated ruler. Four small sections (;1–2 mm) of the placental tissues
were dissected from the maternal side and washed in sterile cold (4C) PBS
to remove excess blood. From these, another 4 small sections (;50 mg)
were cut and fixed in RNALater solution (Qiagen); these samples were
stored at 270C and sent frozen to the Rowett Institute of Nutrition and
Health, Aberdeen, United Kingdom, for RNA extraction and RT-PCR.
RNA isolation and RT-PCR
Total RNAwas isolated from the placenta by homogenizing 50–100 mg
tissue in cold TRI Reagent (Helena Biosciences) on wet ice using a
Dounce homogenizer. RNA was precipitated overnight in isopropanol
and the precipitated RNA was dissolved in diethyl pyrocarbonate–
treated water. RNA quantity and purity were measured spectrophoto-
metrically by measuring OD at absorbance ratios of 260/280 and OD
260/230, respectively, using a NanoDrop 2000c spectrophotometer
(Thermo Fisher Scientific). RNA integrity was determined using an
TABLE 1 Nutritional composition of daily intake of pregnancy
supplements in the Early Nutrition and Immune Development
trial1
Tablets LNS
FeFol MMN PE PE+MMN
Iron, mg 60 60 60 60
Folic acid, μg 400 400 400 400
Vitamin A, μg — 1600 — 1600
Vitamin D, IU — 400 — 400
Vitamin E, mg — 20 — 20
Vitamin C, mg — 140 — 140
Thiamin, mg — 2.8 — 2.8
Riboflavin, mg — 2.8 — 2.8
Niacin, mg — 36 — 36
Vitamin B-6, mg — 2.8 — 2.8
Vitamin B-12, μg — 5.2 — 5.2
Zinc, mg — 30 — 30
Copper, mg — 4 — 4
Selenium, μg — 130 — 130
Iodine, μg — 300 — 300
Energy, kcal — — 746 746
Protein, g — — 20.8 20.8
Lipids, g — — 52.6 52.6
1 FeFol, iron and folate; LNS, lipid-based nutrient supplement; MMN, multiple
micronutrient; PE, protein energy.
FIGURE 1 Subject flowchart summa-
rized according to Consolidated Standards
of Reporting Trials. FeFol, iron and folic
acid; MMN, multiple micronutrient; PE,
protein energy.
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Agilent 2100 Bioanalyzer (Agilent Technologies), according to the
manufacturers instructions. Samples with RNA integrity number #4
were not included in the final analysis because degraded RNA might
affect the quality of the data (20).
RNA (1 mg) was treated with DNase I, Amp Grade (Invitrogen),
according to the manufacturers instructions. Total RNA (200 ng) was
reverse-transcribed into cDNA using a TaqMan MicroRNA Reverse
Transcription Kit (Applied Biosystems), according to the manufacturers
instructions. The reverse-transcription reaction was carried out using a
PTC-100 thermocycler (MJ Research Inc.), under the following condi-
tions; 25C for 10 min, 37C for 60 min, 95C for 5 min, and hold at 4C.
RT-PCR reactions were carried out using a 7500 Fast RT-PCR system
(Applied Biosystems), and each reaction contained 1.5 mL of primer
(Qiagen), 7.5 mL Power SYBR Green PCR Mastermix (Applied Bio-
systems), and 5 mL cDNA in a 15-mL reaction. The PCR reactions were
set at 95C for 15 min, 60C for 10 min (40 repeats), an added
dissociation stage (95C for 15 min), then 60C for 1 min, and finally
95C for 15 min (1 repeat). The results were obtained as cycle threshold
and a single melt curves were obtained for all samples, indicating that a
single PCR product was generated. The cycle threshold values were
obtained for both the gene of interest (Supplemental Table 1) and the
normalizing gene, ubiquitin (QT00234430; Qiagen). Gene expression
was normalized to ubiquitin, and the relative expression of the gene of
interest was expressed as 22DCT.
Statistical analysis
The primary outcomes of this substudy were maternal iron and zinc
status during pregnancy and mRNA expression of placental iron and
zinc transporter proteins. The outcomes according to nutritional in-
tervention arm were analyzed on an intent-to-treat basis, that is,
regardless of adherence to treatment. This study was powered to detect a
treatment effect of $15% on maternal iron and zinc status, assuming a
between-subject spread of 25%, at a power of 90% and a significance
level of 5%. This required 75 mothers/treatment arm.
Data regarding maternal iron status were obtained at booking and
weeks 20 and 30 of gestation, and were initially analyzed as a repeated-
measures 2-factor ANOVA. Because the interaction between nutritional
supplementation and week of gestation was significant (P < 0.001) for all
outcomes, subsequent analyses were based on 1-factor ANOVA for one
time point at a time.Maternal characteristics at enrollment and placental
and neonatal data were analyzed by 1-factor ANOVA.
All ANOVAs were adjusted for the following competing effect
modifiers or confounders (i.e., variables that neither affected the in-
tervention nor were affected by the intervention, but that could in-
fluence the outcomes of interest): gestational age and maternal BMI at
booking, season of birth, and maternal parity. For both the repeated-
measures 2-factor ANOVA and the 1-factor ANOVA per time point,
the maternal iron markers were also adjusted for C-reactive protein,
which was log-transformed to avoid the adjustments being driven by
TABLE 2 Maternal characteristics at enrollment and at 20 and 30 wk of gestation, and neonatal
characteristics at birth1
Characteristic
FeFol group
(n = 75)
MMN group
(n = 75)
PE group
(n = 76)
PE+MMN group
(n = 75) P value2
Maternal
Age, y 30.6 6 6.4 29.6 6 5.5 30.6 6 6.4 30.2 6 6.7 0.74
Weight, kg 55.1 6 7.9 54.5 6 10.0 54.9 6 9.1 55.8 6 9.9 0.83
Height, cm 162.3 6 6.5 161.8 6 5.8 162.6 6 6.0 161.7 6 6.0 0.75
BMI, kg/m2 20.9 6 2.7 20.8 6 3.5 20.7 6 3.2 21.3 6 3.5 0.65
MUAC, cm 26.8 6 2.7 26.4 6 3.5 26.6 6 3.1 26.8 6 3.0 0.82
Gestational age, wk 14.2 6 3.2 14.2 6 3.5 13.9 6 3.3 13.8 6 2.9 0.78
Gestational weight gain, kg 4.91 6 2.90 5.12 6 3.08 5.29 6 2.80 5.35 6 2.95 0.80
Intervention period, wk 26.3 6 3.2 26.1 6 3.6 26.3 6 3.8 26.4 6 3.4 0.96
Prevalence of anemia,3 n (%)
At booking 21 (28.0) 22 (29.3) 25 (32.9) 25 (33.3) 0.874
At 20 wk of gestation 20 (26.7) 25 (33.3) 28 (36.8) 25 (33.3) 0.604
At 30 wk of gestation 32 (42.7)a 26 (34.7)a 53 (69.7)b 46 (61.3)b ,0.0014
Placenta
Weight, g 515 6 100 523 6 91 525 6 97 513 6 103 0.84
Length, cm 18.6 6 1.9 18.5 6 1.3 18.7 6 2.0 18.9 6 2.1 0.73
Breadth, cm 16.6 6 1.6 16.7 6 1.4 16.5 6 1.9 16.5 6 1.5 0.94
Thickness, cm 2.12 6 0.43 2.20 6 0.48 2.15 6 0.39 2.17 6 0.56 0.76
Placental weight–to–birth weight ratio 0.167 6 0.04 0.173 6 0.03 0.178 6 0.03 0.167 6 0.03 0.069
Neonatal
Weight, g 3058 6 402 3040 6 396 2979 6 383 3021 6 420 0.64
Length, cm 49.7 6 1.5 49.5 6 1.7 49.4 6 2.0 49.7 6 2.0 0.63
Head circumference, cm 33.6 6 1.4 33.5 6 2.0 33.2 6 1.3 33.5 6 1.7 0.47
Arm circumference, cm 10.9 6 0.8 10.6 6 0.9 10.6 6 0.7 10.7 6 0.9 0.29
Gestational age, wk 40.5 6 1.3 40.5 6 1.5 40.2 6 1.9 40.2 6 1.5 0.48
Low birth weight,5 n (%) 5 (6.7) 7 (9.3) 7 (9.2) 9 (12.0) 0.744
Preterm birth,5 n (%) 0 (0.0) 1 (1.3) 1 (1.3) 2 (2.7) 0.574
Ponderal Index, g/cm3 3 100 2.50 6 0.36 2.51 6 0.29 2.48 6 0.36 2.46 6 0.29 0.72
1 Values are means6 SDs unless otherwise indicated. Labeled values in a row without a common superscript letter differ (P, 0.05). FeFol,
iron and folate; MMN, multiple micronutrient; MUAC, midupper arm circumference; PE, protein energy.
2 Obtained from 1-factor ANOVA. Placenta and neonatal outcomes were adjusted for gestational age and maternal BMI at booking, season
of birth, and maternal parity; their means have been adjusted accordingly (no adjustments were made for maternal outcomes).
3 Anemia cutoff was hemoglobin ,11.0 g/dL at booking and 30 wk of gestation, and hemoglobin ,10.5 g/dL at 20 wk of gestation.
4 Analyzed with contingency tables.
5 The cutoff for low birth weight was ,2500 g; the cutoff for preterm birth was ,37 wk of gestation.
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outliers. The mean values presented have been adjusted for these con-
founders. When the effect of nutritional supplementation was significant
(P < 0.05), post hoc t tests, based on the ANOVA findings, were used to
explore differences between the nutritional treatment arms.
The assumptions of constant variation and normality required for
ANOVAwere assessed from visual inspection of residual plots; where
necessary, data were log-transformed before proceeding with the
analysis described above. These data are presented as back-transformed
means (adjusted for confounders) and their corresponding back-
transformed 95% CIs. Binary (yes or no) data such as preterm birth
were analyzed using contingency tables; when significant this analysis
was followed by post hoc comparisons based on normal approxima-
tion. All statistical analyses were carried out using Genstat 17.1
statistical software (VSN International Ltd.); however, GraphPad Prism
software was used to present the graphs.
Ethics and governance
The ENID trial and the placental substudy were approved by a joint
Gambia Government/MRC unit, The Gambia Ethics Committee (project
no. SCC1126v2 and L2010.93, respectively). Written informed consent
was obtained from all women before enrollment into the trial. The trial
observed Good Clinical Practice standards and the current version of the
Declaration of Helsinki.
Results
Recruitment and attrition. Between April 2010 and June
2013 a total of 875 women were enrolled in the ENID trial. For
this substudy, 336 women who delivered within a 14-mo period
FIGURE 2 Maternal plasma concentra-
tions of hemoglobin (A), ferritin (B), hepci-
din (C), iron (D), sTfR (E), transferrin (F),
and UIBC (G) at booking and 20 and 30 wk
of pregnancy, by intervention arm. Data
were analyzed by repeated-measures 2-
factor ANOVA, adjusted for gestational
age and maternal BMI at booking, season
of birth, maternal parity, and log-transformed
C-reactive protein. Significance of supple-
mentation (Ps), week (Pw), and its interaction
(Psw) for each concentration are as follows:
hemoglobin: Ps = 0.023, Pw , 0.001, Psw ,
0.001; ferritin: Ps , 0.001, Pw , 0.001,
Psw , 0.001; hepcidin: Ps , 0.001, Pw ,
0.001, Psw , 0.001; iron Ps , 0.001, Pw ,
0.001, Psw , 0.001; sTfR: Ps = 0.019, Pw =
0.005, Psw , 0.001; transferrin: Ps = 0.003,
Pw , 0.001, Psw , 0.001; and UIBC: Ps ,
0.001, Pw , 0.001, Psw , 0.001. Then, for
each time point, data were analyzed by 1-
factor ANOVA adjusted for the variables
listed above. When the effect of supple-
mentation was significant, this ANOVA was
followed by the post hoc t test. Trans-
ferrin and UIBC are presented as ad-
justed means 6 SEMs (n = 71–75).
Hemoglobin, ferritin, hepcidin, and iron
were log-transformed before analysis and
are presented as the back-transformed
adjusted means and their corresponding
back-transformed 95% CIs (n = 66–75).
Means at a given time point without a
common letter differ, P, 0.05. FeFol, iron
and folic acid; MMN, multiple micronu-
trient; PE, protein energy; sTfR, serum
soluble transferrin receptor; UIBC, un-
bound iron-binding capacity.
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(October 2010 to December 2011) were identified for possible
inclusion in this substudy. This included all women who
delivered while in the ENID trial during the 14-mo period
of this substudy. Of the 336 women targeted for inclusion, 8
women were excluded: 3 participants miscarried, 2 participants
had a stillbirth, and 3 had preeclampsia. A total of 27 women
were not included in the placental substudy (FeFol group: n = 7;
MMN group: n = 5; PE group: n = 8; and PE+MMN group: n = 7)
because of missing placental samples. Placental samples were
missed mainly when a mother was referred for hospital delivery
outside the West Kiang study area. The final analysis included
the 301 mother-infant pairs with placental samples collected
(Figure 1). No statistically significant differences were found in
the maternal characteristics at booking (age, BMI, and gesta-
tional age) between the women included in this substudy and
those not included (data not shown).
General subject characteristics at booking. The mean 6 SD
parity of participants was 4.186 2.57 (range: 0–11); mean6 SD
age was 30.26 6.22 y (range: 18–45 y); and mean6 SD BMI (in
kg/m2) was 20.9 6 3.22 (range: 13.9–36.6) at booking. In this
group of women, 20.3%were underweight (BMI <18.5), 70.4%
had a normal BMI (19–24), 6.6% were overweight (BMI 25–
30), and 2.7% were obese (BMI >30). The mean 6 SD
gestational age at booking was 14.0 6 3.24 wk. The prevalence
of anemia (hemoglobin <11.0 g/dL) was 31%; iron deficiency
(ferritin <12 mg/L), 28.6%; and iron deficiency anemia (hemo-
globin <11.0 g/dL and ferritin <12 mg/L), 12.3%.
Maternal and newborn characteristics by supplementation
arm. Within the subgroup of women included in this study,
maternal anthropometric measures and gestational age at booking
did not differ between the intervention arms (Table 2). Further, no
difference was found in the prevalence of low birth weight or
preterm birth between the intervention arms (Table 2). In addition,
neonatal anthropometry and placental measures did not differ
between the intervention arms (Table 2).
Effect of supplementation on maternal iron and zinc status
during pregnancy. No difference was observed in any of the
measured indicators of maternal iron status (hemoglobin,
plasma ferritin, iron, hepcidin, sTfR, transferrin, or UIBC) at
booking. By 20 wk of gestation, no difference was detected for
mean hemoglobin or sTfR concentrations. However, significant
effects of intervention (P < 0.001) were observed with all other
markers, according to supplement type [i.e., LNSs (PE and
PE+MMN groups) compared with tablets (FeFol and MMN
groups)]: plasma ferritin, iron, and hepcidin were significantly
lower in the LNS arms (PE and PE+MMN) compared with the
FeFol and MMN arms (P < 0.003; Figure 2), whereas plasma
transferrin and UIBC were significantly higher in the LNS arms
(P < 0.003; Figure 2) compared with the FeFol and MMN arms.
At week 30 of pregnancy, all maternal iron status indicators
showed significant effects of intervention (P < 0.001); mean
hemoglobin, plasma ferritin, iron, and hepcidin concentrations
were all significantly lower in the LNS arms than in the FeFol
and MMN arms (P < 0.001; Figure 2), whereas mean plasma
sTfR, transferrin, and UIBC values were all significantly higher
in the LNS arms than in the FeFol and MNN arms (P < 0.001;
Figure 2).
The prevalence of maternal anemia at booking and at 20 wk
of gestation was not statistically significant between the inter-
vention arms (Table 2). By 30 wk of gestation, however, maternal
anemia was more prevalent in the LNS intervention arms than in
the FeFol and MMN arms (P < 0.001; Table 2).
At week 30 of gestation, mean plasma zinc concentrations
were higher in the MMN intervention arm than in the FeFol, PE,
and PE+MMN arms (P < 0.001 for all comparisons; Figure 3).
Effect of supplementation on mRNA expression of genes
encoding for placental iron transporter proteins. The
mRNA expression of genes responsible for the transport of
iron across the placenta, including TfR1, divalent metal ion
transporter 1 (DMT1), ferroportin 1 (FPN1), hepcidin, and
zyklopen (ZP), were measured. Transferrin receptor 1 (TfR1)
mRNA expression was 30% (95%CI: 3%, 66%; P = 0.031) and
49% (95% CI: 17%, 90%; P = 0.001) higher in the LNS arms
(PE and PE1MMN) than in the FeFol arm (Figure 4). Further-
more, TfR1 mRNA expression was 29% (95% CI: 1%, 64%;
P = 0.042) higher in the PE1MMN arm than in the MMN arm.
However, placental TfR1mRNA expression between the PE and
MMN intervention arms did not differ (Figure 4).
No differences were observed in the relative gene expression
of DMT1, FPN1, hepcidin, and ZP (P > 0.55) (Supplemental
Figure 1A–D) in the placentas between intervention arms.
FIGURE 3 Maternal plasma zinc concentrations at 30 wk of
gestation, by intervention arm. Data were analyzed by 1-factor
ANOVA, adjusted for gestational age and maternal BMI at booking,
season of birth, and maternal parity. Values are adjusted means 6
SEMs (n = 71–74). Means without a common letter differ, P , 0.05
(post hoc t test). FeFol, iron and folic acid; MMN, multiple micro-
nutrient; PE, protein energy.
FIGURE 4 Placental mRNA expression of TfR1 relative to the
ubiquitin housekeeper, by intervention arm. Placental samples with an
RNA integrity number .4 were analyzed. Log-transformed data were
analyzed by 1-factor ANOVA, adjusted for gestational age and
maternal BMI at booking, season of birth, and maternal parity. Values
are back-transformed adjusted means and their corresponding back-
transformed 95% CIs (n = 69–73). Means without a common letter
differ, P , 0.05. FeFol, iron and folic acid; MMN, multiple micro-
nutrient; PE, protein energy; TfR1, transferrin receptor 1.
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Effect of supplementation on mRNA expression of genes
encoding for placental zinc transporter proteins. We
measured mRNA expression of the intracellular zinc uptake
genes, zrt, irt-like protein (ZIP) 1 (ZIP1), ZIP4, ZIP8, and
ZIP14, and the intracellular zinc exit genes, zinc transporter
(ZNT) 1 (ZNT1) and ZNT4, in the placentas. ZIP1 mRNA
expression was 85% (95% CI: 23%, 177%; P = 0.003) lower in
the PE1MMN intervention arm than in the PE arm (Figure 5A).
No differences between the other arms were observed.
The mRNA expression of ZIP4 was 205% lower (95% CI:
46%, 538%; P = 0.003) and 131% (95% CI: 11%, 380%;
P = 0.025) lower in the PE+MMN arm than in FeFol and PE
intervention arms, respectively (Figure 5B). No other differences
were observed.
Similarly, the mRNA expression of the zinc importer gene
ZIP8 was 100% (95% CI: 22%, 228%; P = 0.006) and 96%
(95% CI: 20%, 219%; P = 0.007) lower in the PE+MMN
arm than in the FeFol and PE intervention arms, respectively,
but no other differences were observed (Figure 5C). The
mRNA expression of ZIP14 showed a trend similar to that
of ZIP4 and ZIP8, but not to a statistically significant level
(P = 0.097) (Supplemental Figure 2A). However, no statis-
tically significant difference was found in the mRNA expression
of the zinc exit genes ZNT1 and ZNT4 between the placentas
from the intervention arms (Supplemental Figure 2B, C).
Effect of supplementation on cord blood iron concentrations.
Mean cord blood hemoglobin and iron concentrations were not
different between the intervention arms (P > 0.098) (Figure 6A,
B). However, the mean ferritin concentration was relatively lower
(P < 0.021) in the cord blood of infants born to women randomly
assigned to the LNS arms (PE and PE+MMN) than in those born
to mothers in the FeFol andMMN intervention arms (Figure 6C).
Discussion
In this study we examined the effect of nutritional interventions
during pregnancy on maternal iron and zinc status and gene
expression of placental iron and zinc transporter proteins in a
cohort of rural African women. Our data is, to our knowledge,
the first evidence from a human population with marginal
nutritional status in which alterations to maternal iron and zinc
status, as a consequence of nutritional supplementation, results
in changes in the gene expression of transporter proteins re-
sponsible for iron and zinc uptake across the placenta. Low
maternal iron values in late pregnancy, as a consequence of the
unexpectedly low iron values of women randomly assigned to
the 2 LNS groups, resulted in higher placental gene expression
of the primary iron uptake protein TfR1 when compared with
their corresponding non-LNS equivalent (no MMN and with
MMN groups). While fetal (cord blood) hemoglobin and iron
data suggest that this placental adaptation (increased TfR1
gene expression) helped improve fetal iron values, fetal ferritin
data indicate lower iron stores for the infants. Furthermore,
our data suggest that the absence of prenatal supplemental zinc
resulted in high gene expression of zinc importer proteins in the
placenta, signaling inadequate fetal zinc acquisition to trigger
the placental response to increase supplies.
During development, the fetus depends entirely on ma-
ternal iron supplied through the placenta for its iron requirement
(16); this supply is facilitated by the primary iron uptake protein,
TfR1, located on the placental apical membrane. The ferric iron
taken up from the maternal circulation by placental TfR1 is
transported across the placenta with the help of a series of iron
transporter proteins, including DMT1, FPN1, and ZP, before
being incorporated onto fetal transferrin. Thus, regulation of
the protein expression and activity of these transporters, most
importantly TfR1, is a critical aspect of fetal iron accretion.
Research in rats (22) and limited data from human observa-
tional studies (23–25) has shown increased expression of
placental TfR1 in response to maternal iron deficiency. In our
study, iron supplementation in LNS format produced an
unexpectedly lower maternal iron status in late pregnancy
compared with iron supplementation in tablet formulation.
The mean plasma concentration of ferritin in the LNS-treated
groups was 14.1 mg/L by 30 wk of gestation; 68% of women
had a plasma ferritin concentration <15 mg/L, indicating
diminished iron stores. In addition, the plasma concentrations
of hepcidin and iron were lower during late pregnancy, in-
dicating a greater systemic demand for iron (26). Plasma sTfR,
transferrin, and UIBC, however, were higher during late
FIGURE 5 Placental mRNA expression of the zinc uptake genes ZIP1
(A), ZIP4 (B), and ZIP8 (C), relative to the ubiquitin housekeeper, by
intervention arm. Placental samples with an RNA integrity number .4
were analyzed. Log-transformed data were analyzed by 1-factor ANOVA,
adjusted for gestational age and maternal BMI at booking, season of birth,
and maternal parity. Values are back-transformed adjusted means and
their corresponding back-transformed 95% CIs (n = 69–73). Means
without a common letter differ, P, 0.05. FeFol, iron and folic acid; MMN,
multiple micronutrient; PE, protein energy; ZIP, zrt, irt-like protein.
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pregnancy in the LNS groups, indicating iron deficiency and
increased cellular iron demand.
Our data indicate that, in situations of reduced maternal
iron concentrations, the gene expression of placental TfR1
protein is higher. Upregulation of placental TfR1 mRNA
expression suggests an increased intrauterine iron demand
and a placental adaptation to try and increase supplies to the
fetus. Although this placental adaptation to maternal iron
deficiency helped improve cord hemoglobin and circulating
iron concentrations, cord ferritin status (reflecting infant iron
stores) was significantly lower in the groups with lower ma-
ternal iron values, suggesting that the adaptation might not be
completely successful. Inadequate iron accretion in utero
might have an implication on the development of fetal organs
such as the brain and kidneys. In the rat iron deficiency model,
placental TfR1 expression is increased, together with its protein
turnover and cycle rate, suggesting an intrauterine stressor, and
the affected fetuses had smaller kidneys than normal and higher
blood pressure in postnatal life (27–29). Furthermore, low iron
stores in early infancy may compromise postnatal development,
especially in populations with high rates of exclusive breastfeed-
ing, as in The Gambia, given the known low amounts of iron in
breast milk.
Despite consistent concentrations of iron (60 mg/d) in
all intervention arms, we observed unexpectedly lower iron
amounts at 30 wk of gestation in the 2 groups receiving LNS. A
previous trial of LNS against other formulations of micro-
nutrient supplementation in infants had shown LNS to be
comparable to iron status (30). Most trials that had used LNS as
an intervention used small-quantity lipid-based supplements
(typically 20 g/d; ;108 kcal) (10, 11). In this trial, women re-
ceiving LNSwere provided with a daily dose of 140 g (;746 kcal).
One possible explanation for this finding is that women in the
FeFol and MMN arms benefitted from additional iron gained
through normal dietary consumption, which might be negated
by the high caloric content of the LNS intervention in this trial.
In this rural Gambian setting, however, where dietary intake
of meat and other foods containing large amounts of iron is low,
we do not consider this explanation likely. We think it is more
likely a consequence of a poorer compliance to supplementa-
tion in the LNS groups. Compliance data collected as part of the
main ENID trial indicate higher compliance among women
receiving the tablet formulation than among those receiving
the LNS formulation (94% compared with 82%, respectively;
P < 0.0001; SEMoore, unpublished results, 2017). This pattern was
consistent within the current subgroup of women (94% compared
with 81%; P < 0.0001). If women were failing to consume the
complete dose of LNS each day, they would not receive the
allocated daily iron supply (60 mg/d).
Whereas the importance of zinc for fetal development has been
recognized (3, 31), less is currently known about the mechanism
of placental transport of zinc to the fetus. As in duodenal epithelial
cells, however, the placental syncytiotrophoblast is assumed to use
the 2 zinc transporter families, zinc importer protein family ZIP
(SLC39) and zinc exporter protein family ZNT (SLC30) to deliver
zinc (32, 33). At the level of the duodenum, some of these trans-
porters are responsive to dietary zinc intake and show a tonic
response to changing zinc levels, increasing deficiency and dropping
as concentrations are restored (34–36). Our data suggest that the
unavailability of dietary zinc in a prenatal supplement (FeFol and
PE) is associated with increased gene expression of zinc uptake
proteins in the placenta, presumably to try andmeet fetal zinc needs.
The key strength of our study is that the trial design allowed
us to directly interrogate the placental response to maternal
iron and zinc concentrations in a population with high rates of
micronutrient deficiency. The large sample size and samples
collected prospectively during pregnancy and at delivery
allowed a detailed investigation of the maternal response to
supplementation and the impact this had on placental expres-
sion of both iron and zinc transporters. Limitations include the
lack of early gestation or cord blood measures of zinc values,
and a later infancy measure of both iron and zinc values.
Further, whereas we indicate gene expression levels, we were
not able to quantify protein levels or to indicate the functional
capacity of these transport proteins.
In conclusion, our data indicate that alterations in maternal
iron and zinc concentrations, as a consequence of nutritional
supplementation during pregnancy, have a regulatory effect on
the gene expression of intrauterine iron and zinc transporter
proteins in the placenta, with consequences for fetal nutritional
status. Despite placental upregulation of TfR1 in response to
maternal deficiency, however, fetal iron markers indicate that
infant status may remain suboptimal in situations of maternal
FIGURE 6 Cord blood concentrations of Hb (A), iron (B), and ferritin
(C), by intervention arm. Data were analyzed by 1-factor ANOVA,
adjusted for gestational age and maternal BMI at booking, season of
birth, and maternal parity. Values are adjusted means6 SEMs (n = 50–
61). Means without a common letter differ, P , 0.05. conc.,
concentration; FeFol, iron and folic acid; Hb, hemoglobin; MMN,
multiple micronutrient; PE, protein energy.
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iron deficiency. Further work is warranted to replicate these
observations and to explore the long-term impact of this
apparent placental regulation on both maternal and infant
micronutrient status. Continued attention should focus on inter-
ventions to improve micronutrient concentrations in women of
reproductive age in settings of nutritional vulnerability.
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